Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study.
作者信息
Jonsdottir Gudbjörg, Lund Sigrún H, Björkholm Magnus, Turesson Ingemar, Wahlin Anders, Mailankody Sham, Blimark Cecilie, Hultcrantz Malin, Porwit Anna, Landgren Ola, Kristinsson Sigurdur Y
机构信息
Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Department of Medicine, Division of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
出版信息
Haematologica. 2016 Apr;101(4):e145-8. doi: 10.3324/haematol.2015.134049. Epub 2015 Dec 17.
Abstract
摘要
相似文献
1
Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study.
Haematologica. 2016 Apr;101(4):e145-8. doi: 10.3324/haematol.2015.134049. Epub 2015 Dec 17.
2
Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.
Am J Clin Pathol. 2012 Dec;138(6):855-66. doi: 10.1309/AJCPOP7APGDT9JIU.
3
Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma.
Leuk Lymphoma. 2019 Dec;60(14):3577-3580. doi: 10.1080/10428194.2019.1633639. Epub 2019 Jul 8.
4
Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries.
Sci Rep. 2016 Feb 24;6:22084. doi: 10.1038/srep22084.
5
Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.
Eur J Haematol. 2021 Aug;107(2):275-282. doi: 10.1111/ejh.13650. Epub 2021 May 28.
6
Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment.
Leukemia. 2016 Jan;30(1):242-7. doi: 10.1038/leu.2015.122. Epub 2015 May 15.
7
Diagnosing therapy-related acute myeloid leukemia with 8% blasts in bone marrow with concomitant plasma cell myeloma.
Blood. 2017 Jul 13;130(2):231. doi: 10.1182/blood-2017-04-779751.
8
Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
Cancer. 2008 Apr 1;112(7):1513-21. doi: 10.1002/cncr.23325.
9
Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry.
Am J Hematol. 2015 Mar;90(3):208-14. doi: 10.1002/ajh.23908. Epub 2015 Jan 16.
10
Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).
Leuk Res. 2013 Jun;37(6):637-40. doi: 10.1016/j.leukres.2013.02.014. Epub 2013 Mar 15.
引用本文的文献
1
A Study on Renal Failure Management in Patients Diagnosed With Multiple Myeloma.
Cureus. 2023 Oct 22;15(10):e47460. doi: 10.7759/cureus.47460. eCollection 2023 Oct.
2
Real-World Pitfalls of Analyzing Real-World Data: A Cautionary Note and Path Forward.
JCO Clin Cancer Inform. 2023 Sep;7:e2300097. doi: 10.1200/CCI.23.00097.
3
Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients.
Cancers (Basel). 2023 Sep 1;15(17):4359. doi: 10.3390/cancers15174359.
4
The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma.
Curr Oncol. 2023 Jun 9;30(6):5615-5630. doi: 10.3390/curroncol30060423.
5
Autologous transplant and second malignancies in MM.
Blood Adv. 2023 Jun 27;7(12):2731-2732. doi: 10.1182/bloodadvances.2023010051.
6
Primary blastic plasmacytoid dendritic cell neoplasm: a US population-based study.
Front Oncol. 2023 May 12;13:1178147. doi: 10.3389/fonc.2023.1178147. eCollection 2023.
7
Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.
Blood Adv. 2023 Jun 27;7(12):2746-2757. doi: 10.1182/bloodadvances.2022009138.
8
Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018.
Cancers (Basel). 2022 Oct 7;14(19):4919. doi: 10.3390/cancers14194919.
9
Secondary B-cell acute lymphoblastic leukaemia in a patient with multiple myeloma.
BMJ Case Rep. 2022 Jun 22;15(6):e249637. doi: 10.1136/bcr-2022-249637.
10
Nivolumab Effective for Gastric and Lung Cancers but Not for Multiple Myeloma in a Multiple Primary Cancer Patient.
Case Rep Hematol. 2021 Aug 26;2021:9965371. doi: 10.1155/2021/9965371. eCollection 2021.
本文引用的文献
1
Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.
JAMA Oncol. 2015 Apr;1(1):88-96. doi: 10.1001/jamaoncol.2014.161.
2
Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.
Haematologica. 2015 Oct;100(10):1340-9. doi: 10.3324/haematol.2015.127548. Epub 2015 Jul 9.
3
Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.
Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):110-4. doi: 10.1016/j.clml.2014.07.001. Epub 2014 Jul 15.
4
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
Lancet Oncol. 2014 Mar;15(3):333-42. doi: 10.1016/S1470-2045(13)70609-0. Epub 2014 Feb 11.
5
Improved long-term survival in multiple myeloma up to the age of 80 years.
Leukemia. 2014 Jun;28(6):1346-8. doi: 10.1038/leu.2014.23. Epub 2014 Jan 14.
6
Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score.
Blood Cancer J. 2011 Sep;1(9):e35. doi: 10.1038/bcj.2011.34. Epub 2011 Sep 16.
7
Myeloma and second primary cancers.
N Engl J Med. 2011 Dec 8;365(23):2241-2. doi: 10.1056/NEJMc1111010.
8
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).
Blood. 2011 Oct 13;118(15):4086-92. doi: 10.1182/blood-2011-05-355743. Epub 2011 Jul 27.
9
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
J Clin Oncol. 2010 May 1;28(13):2259-66. doi: 10.1200/JCO.2009.26.0638. Epub 2010 Apr 5.
10
Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study.
J Clin Oncol. 2010 Feb 10;28(5):830-4. doi: 10.1200/JCO.2009.25.4177. Epub 2009 Dec 28.
Zotero 插件